News

Curaleaf Laboratories Signs Distribution Agreement With Vericura to Expand UK Manufacturing and Distribution of Medical Cannabis Products

Curaleaf Laboratories and Vericura announce a new UK medical cannabis manufacturing and distribution agreement.

Sponsored features editor

Curaleaf Laboratories and Vericura today announced an agreement to strengthen the manufacturing and distribution of medical cannabis products across the United Kingdom.

The collaboration combines Curaleaf Laboratories’ expertise in pharmaceutical manufacturing and distribution with Vericura’s specialist sourcing capabilities, creating an integrated supply chain designed to improve product availability, operational efficiency and continuity of supply for prescribing clinicians, pharmacies and patients.

The partnership reflects both organisations’ shared commitment to advancing access to GMP-manufactured cannabis-based medicines while maintaining the highest standards of quality assurance, regulatory compliance and patient care.

Under the agreement, Curaleaf Laboratories will manufacture Vericura’s medical cannabis products in the UK to GMP standards, with Vericura defining the product range and specifications. By integrating sourcing, manufacturing and distribution, the collaboration aims to develop new cannabis-based medicines to pharmaceutical standards so that healthcare professionals and pharmacies can prescribe and dispense with the confidence they would expect of any other medicine.

Richard Hodgson, Managing Director at Curaleaf Laboratories: “As healthcare professional and patient demand for cannabis-based medicines continues to grow, ensuring a secure, reliable, and efficient supply chain has never been more important. Our agreement with Vericura brings together complementary expertise that will help improve access to GMP medicines while supporting the continued development of the UK’s medical cannabis sector.”

Robert Maxwell, Managing Director at Vericura: “We are proud to partner with Curaleaf Laboratories. Our focus has always been the product itself, cannabis-based medicines built to a genuine pharmaceutical standard. What this partnership adds is reach. Curaleaf Laboratories gives us the manufacturing and distribution strength to put those medicines in the hands of the clinicians who prescribe them and the patients who need them, reliably and at scale.”

The collaboration represents a significant milestone for Vericura as they continue to invest in the UK’s rapidly evolving medical cannabis market. By combining Vericura’s sourcing with Curaleaf’s manufacturing and distribution strength, the partnership will ensure that these medicines are available to prescribing clinicians and their patients.

Both companies remain committed to working closely with healthcare professionals, regulators, and industry partners to support the safe, compliant and sustainable growth of cannabis-based medicines in the UK.

The agreement is effective immediately, with manufacturing and distribution activities commencing in accordance with all applicable UK regulatory requirements.

Healthcare professionals seeking information on prescribing or ordering can reach out to contact Curaleaf Laboratories at: info@curaleaflaboratories.co.uk.

Disclaimer: This press release includes information about cannabis-based products for medicinal use. These products are available in the UK only via prescription from a specialist doctor. This announcement is not intended to promote prescription-only medicines to the public. Treatment decisions should be made by a qualified healthcare professional.